CHLAMYDIA PNEUMONIAE – THE PREVALENCE OF ANTIBODIES IN HEALTHY POPULATION AND IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

  • Darja Keše Inštitut za mikrobiologijo in imunologijo, Medicinska fakulteta, Zaloška 4, 1000 Ljubljana
  • Milan Čižman Klinika za infekcijske bolezni in vročinska stanja, Klinični center, Japljeva 2, 1525 Ljubljana
  • Jožica Marin Inštitut za mikrobiologijo in imunologijo, Medicinska fakulteta, Zaloška 4, 1000 Ljubljana
Keywords: chlamydia, micro-IF, serum, epidemiology, acute infections

Abstract

Background. To determinate the prevalence rates of Chlamydia pneumoniae infections in Slovenia and to evaluate the importance of C. pneumoniae infections at patients with community acquired pneumonia (CAP).
Materials and methods. With the microimmunofluorescence test (micro-IF) we evaluated the presence of C. pneumoniae specific antibodies in 1036 healthy subjects, in two periods of time, in 1991–93 and 1997–1998. We also tested the pair sera collected from 2118 patients with CAP between 1993–1999.
Results. We demonstrated that C. pneumoniae infections are common in our population, as we detected IgG antibodies in 43.1% of healthy population. The prevalence rate of C. pneumoniae infections statistically significant increased in two periods of time. Acute C. pneumoniae infections were proved in 15.9% of all patients with CAP.
Conclusions. C. pneumoniae is important respiratory pathogen also in our community. The infections are more common in older patients. Because C. pneumoniae like other Chlamydia species has tendency to cause chronic disease, it is reasonable to diagnose this bacterium in respiratory patients. It is also recommended to test convalescent sera at serologic laboratory diagnosis.

Downloads

Download data is not yet available.

References

Grayston JT, Kuo CC, Campbell LA, Wang SP. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Syst Bacteriol 1989; 39: 88–90.
Peeling RW, Brunham RC. Chlamydia as pathogens: new species and new issues. Emerg Infect Dis 1996; 2: 307–19.
Orr PH, Peeling RW, Fast M, Brunka J, Duckworth H, Harding GKM, Nicolle LE. Serological study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly. Clin Infect Dis 1996; 23: 1240–5.
Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 15: 757–61.
Allmirall J, Morato I, Riera F, Verdaquer A, Priu R, Coll P, Vidal J, Murgui L, Valls F, Catalan F, Balanzo X. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6: 14–8.
Theunissen HJH, Lemmens-den Toom NA, Burggraaf A, Stolz E, Michel MF. Influence of temperature and relative humidity on the survival of Chlamydia pneumoniae in aerosols. Appl Environ Microbiol 1993; 59: 2589–93.
Allegra L, Blasi F, Centanni S, Cosentini R, Denti F, Raccanelli R. Acute exacerbation of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J 1994; 7: 2165–8.
Grayston JT. Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg 1999; 134: 930–42.
Gupta S, Camm AJ. Chronic infection in the etiology of atherosclerosis – the case for Chlamydia pneumoniae. Clin Cardiol 1997; 20: 829–36.
Grayston JT, Campbell LA, Kuo CC, Mordhort CH, Saikku P, Thom DH, Wang SS. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618–25.
Adamič Š. Temelji biostatike. Ljubljana: Partizanska knjiga, 1980: 77–89.
Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161–8.
Einarsson S, Sigurdsson HK, Magnusdottir SD, Erlendsdottir H, Briem H, Gudmundsson S. Age specific prevalence of antibodies against Chlamydia pneumoniae in Iceland. Scand J Infect Dis 1994; 26: 393–7.
Blasi F, Cosentini R, Schoeller MC, Lupo A, Allegra L. Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan. Thorax 1993; 48: 1261–3.
Puolakkoinen M, Ukkonen P, Saikku P. The seroepidemiology of Chlamydiae in Finland over the period 1971–1987. Epidemiol Infect 1989; 1102: 287–95.
Forsey T, Darougar S, Treharne JT. Prevalence in human beings of antibodies to Chlamydia IOL-207, an atypical strain of Chlamydia. J Infect 1986; 12: 145–52.
Choi TY, Kim AD, Kim SK, Kang JO, Park SS, Jung SR. Prevalence of specific antibodies to Chlamydia pneumoniae in Korea. J Clin Microbiol 1998; 36: 3426–8.
Kanamoto Y, Ouchi K, Mizui M, Ushio M, Usui T. Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan. J Clin Microbiol 1991; 29: 816–8.
Wang JH, Liu YC, Cheng DL, Yeng MY, Chen YS, Chen BC. Seroprevalence of Chlamydia pneumoniae in Taiwan. Scand J Infect Dis 1993; 25: 565–8.
Paltiel O, Kark JD, Leinonen M, Saikku P. High prevalence of antibodies to Chlamydia pneumoniae: determinants of IgG seropositivity among Jerusalem residents. Epidemiol Infect 1995; 114: 465–73.
Freidank HM, Brauer D. Prevalence of antibodies to Chlamydia pneumoniae TWAR in a group of German medical students. J Infect 1993; 27: 89–93.
Koivisto AL, Isoaho R, von Hertzen L, Töyryla M, Laippala P, Kivelä SL, Saikku P. Chlamydial antibodies in an elderly Finnish population. Scand J Infect Dis 1999; 31: 135–9.
Van den Abeele AM, van Renterghem L, Willems K, Plum J. Prevalence of antibodies to Chlamydia pneumoniae in a Belgian population. J Infect 1992; 25: 87–90.
O’Neill C, Murray LJ, Ong GML, O’Reilly DPJ, Evans AE, Bamford KB. Epidemiology of Chlamydia pneumoniae infection in a randomly selected population in a developed country. Epidemiol Infect 1999; 122: 111–6.
Kobayashi S, Morishita T, Miyake T, Fukushi H, Hirai K, Ishihara Y, Isomura S. Prevalence of Chlamydia pneumoniae in Japan. J Infect Dis 1991; 163: 417–8.
Marton A, Karolyi A, Szalka A. Prevalence of Chlamydia pneumonia antibodies in Hungary. Eur J Clin Microbiol Infect Dis 1992; 11: 139–42.
Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumoniae due to unusual Chlamydia psittaci strain. J Infect Dis 1985; 151: 832–9.
Kragsbjerg P, Persson K, Holmberg H. Regional differences of Chlamydia pneumoniae as causative agent of pneumonia in Sweden. Scand J Infect Dis 1992; 24: 113–4.
Gnarpe H, Gnarpe J. Increasing prevalence of specific antibodies toChlamydia pneumoniae in Sweden. Lancet 1993; 341: 381–1.
Karvonen M, Tuomilehto J, Pitkaniemi J, Saikku P. The epidemic cycle of Chlamydia pneumoniae infection in eastern Finland, 1972–1987. Epidemiol Infect 1993; 110: 349–60.
Gnarpe H, Gnarpe J, Lundbäck A. Evidence of 2 Waves of Chlamydia pneumoniae infection in Gävle, Sweden, 1990–96. Scand J Infect Dis 1999; 31: 83–6.
Koivisto AL, Isoaho R, von Hertzen L, Töyryla M, Laippala P, Kivelä SL, Saikku P. Chlamydial antibodies in an elderly Finnish population. Scand J Infect Dis 1999; 31: 135–9.
Blasi F, Cosentini R, Legnani D, Denti F, Allegra L. Incidence of communityacquired pneumonia caused by Chlamydia pneumoniae in Italian patients. Eur J Clin Microbiol Infect Dis 1993; 12: 696–9.
Steinhoff D, Lode H, Ruckdeschel G, Heidrich B, Rolfs A, Fehrenbach FJ, Mauch H, Höffken G, Wagner J. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22: 958–64.
Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowitz S, Friedman MG, Leiononen M, Horowitz O, Manor E, Porath A. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179–84.
Gómez J, Naños V, Gómez JR, Soto MC, Muñoz L, Nuñez ML, Canteras M, ValdØs M. Prospective study of epidemiology and prognostic factors in community – acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996; 15: 556–60.
Torres A, El-Ebiary M. Relevance of Chlamydia pneumoniae in communityacquired respiratory infections. Eur Respir J 1993; 6: 7–8.
Shemer-Avni Y, Lieberman D. Chlamydia pneumoniae induced ciliostasis in ciliated bronchial epithelial cells. J Infect Dis 1995; 171: 1274–8.
SoŁan M, MariniŁ-Fišer N, Kraigher A, Vidmar L. Etiologija pljuŁnice odraslih bolnikov, pridobljene v domaŁem okolju. In: Strle F, ¨ižman M ed. Ljubljana: Infektološki simpozij 1998. Zbornik predavanj. Medicinski razgledi, 1998. Ljubljana.
Heiskanen-Kosma T, Korppi M, Laurila A, Jokinen C, Kleemola M, Saikku P. Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study. Scand J Infect Dis 1999; 31: 255–9.
Lund-Olsen I, Lundbäck A, Gnarpe J, Gnarpe H. Prevalence of specific antibodies to Chlamydia pneumoniae in children with acute respiratory infections. Acta Pediatr 1994; 83: 1143–5.
Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis and treatment. J Infect Dis 1995; 21: S244–52.
Kutlin A, Roblin PM, Hammerschlag MR. Antibody response to Chlamydia pneumoniae infection in children with respiratory illness. J Infect Dis 1998; 177: 720–4.
Lieberman D, Ben-Yaakov M, Lazarowich Z, Porath A, Schlaeffer F, Lieberman D, Leinonen M, Saikku P, Horowitz O, Boldur I. Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients. Infection 1996; 24: 109–14.
Published
2017-04-16
How to Cite
1.
Keše D, Čižman M, Marin J. CHLAMYDIA PNEUMONIAE – THE PREVALENCE OF ANTIBODIES IN HEALTHY POPULATION AND IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA. ZdravVestn [Internet]. 16Apr.2017 [cited 15Nov.2019];70(6). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/2567
Section
Professional Article